| Description |
1 online resource |
| Series |
Immunology and immune system disorders |
|
Immunology and immune system disorders.
|
| Contents |
""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""Contents ""; ""Preface ""; ""The Risk of Infection in Patients Treated with Infliximab ""; ""Abstract ""; ""1. Definition and Functions of Tumour Necrosis Factor ""; ""2. Anti-TNF Mechanism of Action: Infliximab ""; ""3. Risk of Infections in the Use of Infliximab: Evidence""; ""4. Risk of Infection from the Use of Anti-TNF (Inflximab): Mechanisms Involved""; ""5. Other Risk Factors for Infection in Patients Treated with Infliximab ""; ""6. Infections ""; ""Bacterial Infections"" |
|
""Listeria """"Tuberculosis ""; ""Virus ""; ""Fungal Infections ""; ""Histoplasmosis ""; ""Coccidioidomycosis ""; ""Cryptococcosis ""; ""Aspergillosis ""; ""Candidiasis""; ""Pneumocystosis ""; ""7. Special Situations""; ""Perisurgical Infections ""; ""Hepatitis B Virus Infection ""; ""Hepatitis C Virus Infection ""; ""HIV Infection ""; ""Vaccines ""; ""Conclusions ""; ""References ""; ""Infliximab in Inflammatory Bowel Disease ""; ""Abstract ""; ""Pharmacology""; ""Uses ""; ""Inflammatory Crohn�s Disease ""; ""Fistulizing Crohn�s Disease ""; ""Ulcerative Colitis""; ""Mucosal Healing "" |
|
""Pouchitis""""Extraintestinal Manifestations ""; ""Limitations ""; ""Predictors of Response to Infliximab ""; ""Infections ""; ""Malignancies and Lymphoma ""; ""Cutaneous, Neurological and Liver Manifestations ""; ""Congestive Heart Failure ""; ""Pregnancy ""; ""References ""; ""Infliximab: Up-to-Date on Indications and Warnings ""; ""Abstract ""; ""1. Introduction""; ""2. Pharmacology""; ""2.1. Structure and Mechanisms of Action""; ""2.2. Absorption ""; ""2.3. Distribution ""; ""2.4. Metabolism and Excretion ""; ""2.5. Dosage and Administration ""; ""2.6. Pharmacogenomics"" |
|
""D) Chronic Eczema """"E) Hidradenitis Susppurativa (HS) ""; ""3.3. Other Verified Uses ""; ""a) SAPHO Syndrome ""; ""b) Kawasaki Disease ""; ""c) Pulmonary Fibrosis ""; ""d) Cap Polyposis ""; ""e) Postresuscitation Myocardial Dysfunction ""; ""f) B-Chronic Lymphocytic Leukemia ""; ""g) Diabetic Macular Edema ""; ""4. Warnings and Limitations""; ""4.1. Serious Infections ""; ""4.2. Malignancies ""; ""4.3. Hepatitis B virus Reactivation ""; ""4.4. Hepatotoxicity ""; ""4.5. Patients with Heart Failure ""; ""4.6. Hematological and Vascular Events ""; ""4.7. Hypersensitivity "" |
| Bibliography |
Includes bibliographical references and index |
| Notes |
English |
|
Description based on print version record |
| Subject |
Infliximab.
|
|
Infliximab -- Therapeutic use
|
|
Anti-inflammatory agents.
|
|
Autoimmune Diseases -- drug therapy
|
|
Anti-Inflammatory Agents
|
|
MEDICAL -- Immunology.
|
|
Autoimmune diseases -- Chemotherapy
|
|
Infliximab
|
| Form |
Electronic book
|
| Author |
Medrano Acevedo, Antonio D
|
|
Fajardo Gaitan, Montserrat
|
| LC no. |
2020677201 |
| ISBN |
9781619423459 |
|
1619423456 |
|
